Open to all ISPOR Members and Non-members

Presented by:

  • Sven Klijn, MSc
  • Elisabeth Fenwick, PhD
  • John Borrill, MSc

Tuesday, October 6, 2020 
10:00AM EDT | 3:00PM BST | 4:00PM CEST

Click here for time zone conversion

Determining reliable estimates of the survival gain offered by new therapies compared to standard of care is a critical component in establishing their incremental cost-effectiveness. Inaccurate results will lead to inappropriate estimates of lifetime health benefit and ultimately sub-optimal healthcare decision-making. New technologies with different mechanisms of action can have distinct and complex patterns of survival bringing new challenges for the assessment of their long-term benefit.

In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.

After attending this webinar, participants will be able to:

  • Understand the pivotal role that survival extrapolation plays in Health Technology Assessment (HTA) and explain the standard approach that is used for this analysis 
  • Identify the mechanism of action of cancer immunotherapy and some of the key challenges for estimating the incremental survival gain offered by these agents
  • Identify the different survival extrapolation techniques that could be used in HTA submissions for cancer immunotherapies including their strengths and limitations
  • Provide some pointers on the appropriate selection and validation of survival extrapolation method for this class of drug  

Register Here

Brought to you by:

Pharmerit Logo


Sven Klijn, MSc, Associate Director, Modeling & Meta-Analysis, Pharmerit – an OPEN Health company, Rotterdam, The Netherlands


Elisabeth Fenwick, PhD, Senior Director, Modeling & Meta-Analysis, Pharmerit – an OPEN Health company, Oxford, UK 

John Borril, MSc, Director WW HEOR Bristol Myers Squibb, Uxbridge, UK


Please note: On the day of the scheduled webinar, the first 500 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 weeks after the scheduled Webinar.

Reservations are on a first-come, first-served basis for all ISPOR members.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now